MiNK Therapeutics, Inc.
NASDAQ:INKTBiotechnology
-$0.35 today
- Market cap
- $52.17M
- Beta
- 0.47
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$2.60
Volume 0.01M
Average 0.05M
INKT Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
MiNK Therapeutics, Inc.NASDAQ: INKT
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q1 FY2026 stock-based compensation of $630.39K rose 6.6% year over year, behind the +116111.4% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 100.0% from the prior quarter. Over 3 fiscal years it compounded at -4.0% a year.
Context
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +6.6% toward the trailing-twelve-month pace of +116111.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 2.67M USD
- Year-over-year change
- +47.7%
- 4-year CAGR
- +11.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.67M | +47.7% |
| FY2024 | 2024-12-31 | 1.81M | -53.1% |
| FY2023 | 2023-12-31 | 3.86M | +27.5% |
| FY2022 | 2022-12-31 | 3.03M | +73.5% |
| FY2021 | 2021-12-31 | 1.74M | — |
Stock-Based Compensation vs competitors
How INKT compares with its peers on the latest reported figures
- INKT's LTM Mar 2026 stock-based compensation of $2.67B is the 2nd largest of the 9 companies compared; the peer median is $2.68M.
- Its year-over-year change of +116111.4% is the 2nd highest of 9, against a peer median of -34.5%.
- Over three fiscal years its annual growth of -4.0% compares with a peer median of -8.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $4.27B | +453006.6% | — | — |
| LTM Mar 2026 | $2.67B | +116111.4% | -4.0% | — | |
| LTM Mar 2026 | $5.14M | -37.3% | +4.9% | 1543.3% | |
| LTM Jun 2026 | $3.79M | -50.8% | -5.5% | 18.1% | |
| LTM Mar 2026 | $2.72M | -37.2% | -10.8% | — | |
| LTM Mar 2026 | $2.63M | -22.6% | -21.7% | — | |
| LTM Mar 2026 | $1.96M | -41.6% | — | 5.3% | |
| LTM Mar 2026 | $1.79M | -31.8% | +5.7% | — | |
| LTM Mar 2026 | $367K | +43.4% | -60.2% | 16.0% | |
| Peer median (excluding INKT) | $2.68M | -34.5% | -8.2% | 17.0% | |
Competitors are the stored peer set for INKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (30.21M) | (27.99M) | (22.46M) | (10.78M) | (12.49M) |
| Depreciation & Amortization | 77.96K | 121.75K | 204.62K | 215.44K | 181.75K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.74M | 3.03M | 3.86M | 1.81M | 2.67M |
| Change in Working Capital | 3.74M | 8.77M | 2.9M | 459.73K | 3.29M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (152.04K) | 2.66M | (1.92M) | (1.18M) | 689.71K |
| Other Working Capital | 3.89M | 6.11M | 4.81M | 1.64M | 2.6M |
| Other Non-Cash Items | 11.83M | (2.79M) | (266.78K) | (1.26M) | 424.63K |
| Operating Cash Flow | (12.83M) | (18.87M) | (15.76M) | (9.56M) | (5.93M) |
| Capital Expenditures | (248.98K) | (250.05K) | (73.56K) | (4) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (248.98K) | (250.05K) | (73.56K) | 0 | 0 |
| Debt Repayment | 9.46M | 0 | 0 | 5M | 0 |
| Common Stock Issued | 39.8M | 0 | 0 | 5.8M | 14.9M |
| Common Stock Repurchased | 0 | (157.19K) | (477.64K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 150 | 1.6K | 70.47K | 19.99K | (173.35K) |
| Financing Cash Flow | 49.26M | (155.6K) | (407.17K) | 10.82M | 14.72M |
| Effect of Forex Changes | 16.9K | 19.39K | (25.25K) | (54.7K) | (13.43K) |
| Net Change in Cash | 36.2M | (19.25M) | (16.27M) | 1.21M | 8.78M |
| Free Cash Flow | (13.08M) | (19.12M) | (15.84M) | (9.56M) | (5.93M) |
MiNK Therapeutics, Inc.
NASDAQ:INKT
Intrinsic Alpha fair value
Locked
Current Price
$10.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.